title: Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
abstract: This observation reports that a hepatitis B virus (HBV) reactivation, as the result of hepatitis C virus (HCV) eradication on a dominant HCV coinfected HBV/HCV patient, was subsequently prevented by treating both viral infections together. This finding raises the question as to whether preemptive HBV treatment should be prescribed along with HCV treatment to prevent HBV from being reactive after HCV eradication in coinfected HBV/HCV patients.
authors.affiliation: Gastroenterology Department, Hyères Hospital, Hyères, France. crenou@ch-hyeres.fr
authors.forename: Christophe
authors.initials: C
authors.lastname: Renou
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Cadranel
authors.forename: Alexandre
authors.initials: A
authors.lastname: Pariente
authors.forename: Guillaume
authors.initials: G
authors.lastname: Pénaranda
authors.forename: Marc
authors.initials: M
authors.lastname: Bourlière
authors.forename: Philippe
authors.initials: P
authors.lastname: Halfon
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Igual
authors.forename: Abdelouahid
authors.initials: A
authors.lastname: Harafa
authors.forename: Pierre
authors.initials: P
authors.lastname: Muller
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Bertrand
authors.forename: René
authors.initials: R
authors.lastname: Laugier
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy / Q000821:virology; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; C053001:adefovir; D000225:Adenine